Combined inhibition of DNMT and HDAC blocks the tumorigenicity of cancer stem-like cells and attenuates mammary tumor growth

Cancer Research

Volumn 76, Issue 11, 2016, Pages 3224-3235

  Pathania, Rajneesh ^a   Ramachandran, Sabarish ^b   Mariappan, Gurusamy ^a   Thakur, Priyanka ^a   Shi, Huidong ^a   Choi, Jeong Hyeon ^a   Manicassamy, Santhakumar ^a   Kolhe, Ravindra ^a   Prasad, Puttur D ^a   Sharma, Suash ^a   Lokeshwar, Bal L ^a   Ganapathy, Vadivel ^b   Thangaraju, Muthusamy ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; BUTYRIC ACID; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE INHIBITOR; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; RNA; ANTINEOPLASTIC ANTIMETABOLITE; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; HDAC1 PROTEIN, HUMAN; HISTONE DEACETYLASE 1; MESSENGER RNA; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER STEM CELL; CARCINOGENICITY; CELL SELF-RENEWAL; CENTROMERE; CHROMATIN; CONTROLLED STUDY; DNA DAMAGE; DNA MODIFICATION; DNA REPAIR; DRUG RESISTANCE; ENZYME INHIBITION; EPIGENETICS; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIOSENSITIVITY; RNA SEQUENCE; STEM CELL; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CARCINOMA, BASAL CELL; CELL PROLIFERATION; COMBINATION DRUG THERAPY; DRUG EFFECTS; ENZYME IMMUNOASSAY; FEMALE; GENETICS; HIGH THROUGHPUT SEQUENCING; METABOLISM; NONOBESE DIABETIC MOUSE; NUDE MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; AZACITIDINE; BIOMARKERS, TUMOR; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA, BASAL CELL; CELL PROLIFERATION; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DRUG THERAPY, COMBINATION; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, NUDE; MICE, SCID; NEOPLASTIC STEM CELLS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 84975078260     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-2249     Document Type: Article

References (48)

1. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008;100:672-9.
2. Park CY, Tseng D, Weissman IL. Cancer stem cell-directed therapies: recent data from the laboratory and clinic. Mol Ther 2009;17:219-30.
3. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009;138:645-59.
4. Curtis SJ, Sinkevicius KW, Li D, Lau AN, Roach RR, Zamponi R, et al. Primary tumor genotype is an important determinant in identification of lung cancer propagating cells. Cell Stem Cell 2010;7:127-33.
5. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012;21:309-22.
6. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11.
7. Ting AH, McGarvey KM, Baylin SB. The cancer epigenome-components and functional correlates. Genes Dev 2006;20:3215-31.
8. You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 2012;22:9-20.
9. Brower V. Epigenetics: Unravelling the cancer code. Nature 2011;471:S12-3.
10. Pathania R, Ramachandran S, Elangovan S, Padia R, Yang P, Cinghu S, et al. DNMT1 is essential for mammary and cancer stem cell maintenance and tumorigenesis. Nat Commun 2015;6:6910.
11. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006;7:21-33.
12. Esteller M.Epigenetics in cancer. N Engl J Med 2008;358:1148-59.
13. Ramchandani S, Bhattacharya SK, Cervoni N, Szyf M. DNA methylation is a reversible biological signal. Proc Natl Acad Sci U S A 1999;96:6107-12.
14. Flotho C, Claus R, Batz C, Schneider M, Sandrock I, Ihde S, et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 2009;23:1019-28.
15. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Köhler G, Wijermans P, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 2002;100:2957-64.
16. Gros C, Fahy J, Halby L, Dufau I, Erdmann A, Gregoire JM, et al. DNA methylation inhibitors in cancer: recent and future approaches. Biochimie 2012;94:2280-96.
17. Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotechnol 2010;28:1069-78.
18. Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 2009;138:822-9.
19. Visvader JE. Cells of origin in cancer. Nature 2011;469:314-22.
20. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. New Engl J Med 2004;351:657-67.
21. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 1992;89:10578-82.
22. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009;15:907-13.
23. Lo PK, Kanojia D, Liu X, Singh UP, Berger FG, Wang Q, et al. CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFbeta signaling. Oncogene 2012;31:2614-26.
24. Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castillo B, Pérez-Martínez MC, Cufí S, Del Barco S, et al. Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into denovo resistance to trastuzumab (Herceptin). Int J Oncol 2010;37:669-78.
25. Martin-Castillo B, Oliveras-Ferraros C, Vazquez-Martin A, Cufí S, Moreno JM, Corominas-Faja B, et al. Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin). Cell Cycle 2013;12:225-45.
26. Santner SJ, Dawson PJ, Tait L, Soule H D, Eliason J, Mohamed AN, et al. Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res Treat 2001;65:101-10.
27. Turner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan R, et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 2010;29:2013-23.
28. Miller FR, Miller BE, Heppner GH. Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastasis 1983;3:22-31.
29. Dunlop MH, Dray E, Zhao W, San Filippo J, Tsai MS, Leung SG, et al. Mechanistic insights into RAD51-associated protein 1 (RAD51AP1) action in homologous DNA repair. J Biol Chem 2012;287:12343-7.
30. Wiese C, Dray E, Groesser T, San Filippo J, Shi I, Collins DW, et al. Promotion of homologous recombination and genomic stability by RAD51AP1 via RAD51 recombinase enhancement. Mol Cell 2007;28:482-90.
31. Helleday T. Homologous recombination in cancer development, treatment and development of drug resistance. Carcinogenesis 2010;31:955-60.
32. Janke C, Ortiz J, Lechner J, Shevchenko A, Shevchenko A, Magiera MM, et al. The budding yeast proteins Spc24p and Spc25p interact with Ndc80p and Nuf2p at the kinetochore and are important for kinetochore clustering and checkpoint control. EMBO J 2001;20:777-91.
33. Yuen KW, Montpetit B, Hieter P. The kinetochore and cancer: what's the connection? Curr Opin Cell Biol 2005;17:576-82.
34. Ganem NJ, Storchova Z, Pellman D. Tetraploidy, aneuploidy and cancer. Curr Opin Genet Dev 2007;17:157-62.
35. Zhang W, Tan W, Wu X, Poustovoitov M, Strasner A, Li W, et al. A NIK-IKKalpha module expands ErbB2-induced tumor-initiating cells by stimulating nuclear export of p27/Kip1. Cancer Cell 2013;23:647-59.
36. van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002;161:1991-6.
37. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992;52:1399-405.
38. Cheung KJ, Gabrielson E, Werb Z, Ewald AJ. Collective invasion in breast cancer requires a conserved basal epithelial program. Cell 2013;155:1639-51.
39. Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, et al. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 2006;8:R59.
40. Song LJ, Zhang WJ, Chang ZW, Pan YF, Zong H, Fan QX, et al. PU.1 Is Identified as a Novel Metastasis Suppressor in Hepatocellular Carcinoma Regulating the miR-615-5p/IGF2 Axis. Asian Pacific J Cancer Prevent 2015;16:3667-71.
41. Schoch C, Kern W, Kohlmann A, Hiddemann W, Schnittger S, Haferlach T. Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile. Genes Chromosomes Cancer 2005;43:227-38.
42. Henson SE, Tsai SC, Malone CS, Soghomonian SV, Ouyang Y, Wall R, et al. Pir51, a Rad51-interacting protein with high expression in aggressive lymphoma, controls mitomycin C sensitivity and prevents chromosomal breaks. Mut Res 2006;601:113-24.
43. Wang Y, Yu Q, Cho AH, Rondeau G, Welsh J, Adamson E, et al. Survey of differentially methylated promoters in prostate cancer cell lines. Neoplasia 2005;7:748-60.
44. Hori T, Haraguchi T, Hiraoka Y, Kimura H, Fukagawa T. Dynamic behavior of Nuf2-Hec1 complex that localizes to the centrosome and centromere and is essential for mitotic progression in vertebrate cells. J Cell Sci 2003;116:3347-62.
45. MacLeod AR, Rouleau J, Szyf M. Regulation of DNA methylation by the Ras signaling pathway. J Biol Chem 1995;270:11327-37.
46. McCleland ML, Kallio MJ, Barrett-Wilt GA, Kestner CA, Shabanowitz J, Hunt DF, et al. The vertebrate Ndc80 complex contains Spc24 and Spc25 homologs, which are required to establish and maintain kinetochore-microtubule attachment. Curr Biol 2004;14:131-7.
47. DeLuca JG, Dong Y, Hergert P, Strauss J, Hickey JM, Salmon ED, et al. Hec1 and nuf2 are core components of the kinetochore outer plate essential for organizing microtubule attachment sites. Mol Bio Cell 2005;16:519-31.
48. Sun SC, Lee SE, Xu YN, Kim NH. Perturbation of Spc25 expression affects meiotic spindle organization, chromosome alignment and spindle assembly checkpoint in mouse oocytes. Cell cycle 2010;9:4552-9.